High Parameter Flow Cytometry and A New Computational Platform Reveal Unique Cell Phenotypes That Predict Melanoma Outcomes

For patients with metastatic melanoma, immunotherapies have revolutionized treatment, but many patients fail to respond, and mechanisms of resistance remain unclear. Moreover, many immunotherapy modalities are in clinical trials, but there are few biomarkers known to predict response. We believe a major reason is the lack of in-depth immune profiling, and a lack of tools that completely and comprehensively examine datasets. The work presented here represents a new approach to biomarker research, which combines 30-parameter flow cytometry (HPFlow) with CytoBrute, a rapid computation platform that performs high parameter Boolean analysis that otherwise might be intractable.